Core Viewpoint - Laimei Pharmaceutical announced participation in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected in the upcoming procurement process [1] Group 1: Company Announcement - Laimei Pharmaceutical and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., participated in the bidding organized by the National Centralized Procurement Office for drugs whose agreements have expired [1] - The National Centralized Procurement Office published the proposed selection results on February 10, 2026, indicating that some products from Laimei Pharmaceutical and Hunan Kangyuan are expected to be selected [1]

Core Viewpoint - Lai Mei Pharmaceutical (300006.SZ) and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the bidding for the continuation procurement organized by the National Organization for Drug Procurement, with some products expected to be selected in the upcoming procurement [1] Group 1 - The company and Hunan Kangyuan recently engaged in the bidding process for the continuation procurement of drugs whose agreements have expired [1] - The National Organization for Drug Procurement announced the proposed selection results on February 10, 2026 [1] - Some products from the company and Hunan Kangyuan are anticipated to be selected in this continuation procurement [1]